About the role
AI summarisedSenior-level scientist role focused on pharmacology for RNA-based therapeutics targeting cardiovascular and metabolic diseases. Responsible for designing and executing end-to-end in vitro and in vivo studies using oligonucleotides (ASO/siRNA) in obesity and MASH models, including metabolic assays, rodent PK/PD studies, and regulatory compliance.
ResearchOnsite
Key Responsibilities
- Design and plan integrated in vitro and in vivo study strategies aligned to project questions
- Analyse, interpret, and synthesise data into decision-quality outcomes
- Present clear conclusions and recommendations at internal project reviews
- Maintain timelines, anticipate risks, and troubleshoot methodically
- Perform delivery/transfection of ASOs and siRNAs (training provided if needed)
- Execute dose-response and time-course studies to assess target engagement, potency, durability, and functional phenotypic outcomes
- Evaluate off-target and cytotoxicity effects, and assay robustness
- Culture and maintain primary and immortalised cell lines relevant to metabolic disease
- Develop and optimise in vitro models of steatosis, lipid metabolism, insulin resistance, and energy expenditure
- Conduct lipid accumulation and steatosis assays (Oil Red O, BODIPY)
- Run glucose uptake, insulin sensitivity, and fatty acid oxidation assays
Requirements
- Master's degree in Life Sciences, Pharmacology, Biomedical Sciences, or a related field
- Significant hands-on experience (10+ years) spanning both metabolic in vitro models/assays and rodent in vivo pharmacology (dosing, tissue collection)
- Demonstrated ability to plan, execute, analyse, and report studies with minimal supervision
- Direct experience developing, writing, and securing IACUC protocols (not only adherence) to enable in vivo studies
- Strong execution discipline: controls, documentation, reproducibility, data integrity
- Collaborative team player with strong communication skills and translational scientific thinking
- Prior experience working with RNA modalities (siRNA/ASO) is desired but not required